Previous close | 45.78 |
Open | 45.64 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 800 |
Day's range | 45.21 - 46.05 |
52-week range | 31.45 - 81.72 |
Volume | |
Avg. volume | 2,266,067 |
Market cap | 8.24B |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.29 |
Earnings date | 30 Oct 2023 - 03 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 51.29 |
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
SOMERSET, N.J., September 18, 2023--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023.